Gilead’s Kite to acquire CAR T-therapies developer Tmunity Therapeutics
Kite, an arm of Gilead Sciences, has agreed to acquire Tmunity Therapeutics, a Philadelphia-based clinical-stage biotech company focused on next-generation CAR T-therapies and technologies, for an undisclosed amount. Under the agreement, Kite will acquire all the shares of Tmunity Therapeutics, which it already doesn’t own. The acquisition aligns with Kite’s current in-house cell therapy research […]